American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Online Submission
Customer Services
Subscription information
Online sample issue
Purchase articles
reprints & permissions
Advertising
Contact Springer Nature
nature.com
Original Article
Neuropsychopharmacology (2002) 26 368-375.10.1038/S0893-133X(01)00370-0

Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder

Robert E McCullumsmith MD, Ph.D and James H Meador-Woodruff MD
Mental Health Research Institute and Department of Psychiatry, University of Michigan, Ann Arbor, MI USA

Correspondence: Dr Robert E McCullumsmith, Mental Health Research Institute and Department of Psychiatry, University of Michigan, 205 Zina Pitcher Place, Ann Arbor, MI 48109-0720; Tel.: 734-936-2061; E-mail: smithrob@umich.edu

ABSTRACT

Because abnormalities of glutamatergic neurotransmission in psychiatric illness are likely not limited to glutamate receptor expression, we investigated expression of excitatory amino acid transporters (EAATs) in the striatum. The EAATs, normally expressed in both glia (EAAT1 and EAAT2) and neurons (EAAT3 and EAAT4), have previously been implicated in Huntington's disease, amyotrophic lateral sclerosis, and schizophrenia. In this study, we investigated striatal expression of transcripts encoding EAATs in tissue from mood disordered and schizophrenic subjects. With probes designed for the human EAAT1, EAAT2, EAAT3, and EAAT4 transcripts, we performed in situ hybridization and detected decreased expression of EAAT3 and EAAT4 transcripts in the striatum in bipolar disorder. We also detected decreased EAAT3 transcript expression in schizophrenia and decreased EAAT4 transcript expression in major depressive disorder. These results suggest that changes in striatal transporter mRNA expression are restricted to neuronal EAATs and extend the body of evidence implicating abnormal glutamatergic neurotransmission in schizophrenia and mood disorders.

Keywords: Glutamate, Striatum, Mood disorder, Antidepressant, Mood stabilizer, Affective disorder
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 2002 by the American College of Neuropsychopharmacology